Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran

This study was conducted to find the etiology of acute diarrhea in Iranian children and determine the antimicrobial resistance patterns. The pathogenic bacteria were recovered from 110/269 (40.9%) diarrheal fecal samples with the following profiles: the most predominant pathogen was diarrheagenic Es...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Microbial drug resistance (Larchmont, N.Y.) N.Y.), 2017-12, Vol.23 (8), p.137-1044
Hauptverfasser: Aminshahidi, Maneli, Arastehfar, Amir, Pouladfar, Gholamreza, Arman, Esmayil, Fani, Fereshteh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1044
container_issue 8
container_start_page 137
container_title Microbial drug resistance (Larchmont, N.Y.)
container_volume 23
creator Aminshahidi, Maneli
Arastehfar, Amir
Pouladfar, Gholamreza
Arman, Esmayil
Fani, Fereshteh
description This study was conducted to find the etiology of acute diarrhea in Iranian children and determine the antimicrobial resistance patterns. The pathogenic bacteria were recovered from 110/269 (40.9%) diarrheal fecal samples with the following profiles: the most predominant pathogen was diarrheagenic Escherichia coli (DEC) (43.6%), comprising enteroaggregative E. coli (23.6%), enteropathogenic E. coli (10.9%), enteroinvasive E. coli (5.5%), and enterotoxigenic E. coli (3.6%); Shigella spp. (37.3%), Salmonella spp. (12.7%) and Campylobacter jejuni (6.4%) were ranked second and fourth in terms of prevalence, respectively. The rates of extended-spectrum beta-lactamase (ESBL) production were 66.7% and 53.7% in DEC and Shigella , respectively. Resistance to ampicillin (AMP) (95.1%), trimethoprim/sulfamethoxazole (SXT) (73.2%), azithromycin (ATH) (21.9%), and ciprofloxacin (CIP) (14.6%) was observed among Shigella isolates. Multidrug resistance phenotype was observed in 24.4% (10/41) of Shigella isolates, with the most common pattern of resistance to cefotaxime, ceftriaxone, ceftazidime, AMP, SXT, and ATH. This study indicates an alarming increase in the ESBL production of DEC and Shigella spp. and identifies them as the two most prevalent diarrhea-causing enteropathogens in the region. The results show that CIP could be an alternative to third-generation cephalosporins against these two pathogens. Therefore, it is proposed that further investigation be done in the pursuit of alternative antibiotics that are effective against the resistant cases. For instance, one study could look into the comparative clinical effectiveness of third-generation cephalosporins versus CIP, the latter not being presently the drug of choice for the treatment of acute diarrhea in children in Iran.
doi_str_mv 10.1089/mdr.2017.0204
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5709696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1961034995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-e55a05a01efb7cd185aaa351852872fb259b6093ef818c17d3da7fd8064f4aae3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEoqVw5IosceFAFjsfTswBaSkLrbQSiJazNbEnG1eJvdgOBf4UfxFH21bABcnS2ONH78zYb5Y9ZXTFaCteTdqvCsqaFS1odS87ZqJkeVtV7f20pw3PeSGqo-xRCFeU0prx8mF2VAhGeVnUx9mvdwa8HxB2aI0im6AG9EYNBohyoyFgNbkYzA7HEci1iQM5M7uBfIaIxPVk8z2i1ajziz2q6OeJvMUI-RZUhAkCkk_e6VlF4-xrcnnt0hm1m4wFG8kmpUe3MwpGsk71Y1gk12pO2rdtEWOX-h5-viTnHuzj7EEPY8AnN_Ek-_J-c3l6lm8_fjg_XW9zVRU05ljXQNNi2HeN0qytAaCsUyzapui7ohYdp6LEvmWtYo0uNTS9bimv-goAy5PszUF3P3cTapW68zDKvTcT-B_SgZF_31gzyJ37JuuGCi54EnhxI-Dd1xlDlJMJanlGi24OkgnOaFkJUSf0-T_olZu9TeMtlEir4TRR-YFS3oXgsb9rhlG5WEEmK8jFCnKxQuKf_TnBHX379wkoD8CSBmtHgx36-B_Z3xEyw68</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1969969760</pqid></control><display><type>article</type><title>Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran</title><source>Alma/SFX Local Collection</source><creator>Aminshahidi, Maneli ; Arastehfar, Amir ; Pouladfar, Gholamreza ; Arman, Esmayil ; Fani, Fereshteh</creator><creatorcontrib>Aminshahidi, Maneli ; Arastehfar, Amir ; Pouladfar, Gholamreza ; Arman, Esmayil ; Fani, Fereshteh</creatorcontrib><description>This study was conducted to find the etiology of acute diarrhea in Iranian children and determine the antimicrobial resistance patterns. The pathogenic bacteria were recovered from 110/269 (40.9%) diarrheal fecal samples with the following profiles: the most predominant pathogen was diarrheagenic Escherichia coli (DEC) (43.6%), comprising enteroaggregative E. coli (23.6%), enteropathogenic E. coli (10.9%), enteroinvasive E. coli (5.5%), and enterotoxigenic E. coli (3.6%); Shigella spp. (37.3%), Salmonella spp. (12.7%) and Campylobacter jejuni (6.4%) were ranked second and fourth in terms of prevalence, respectively. The rates of extended-spectrum beta-lactamase (ESBL) production were 66.7% and 53.7% in DEC and Shigella , respectively. Resistance to ampicillin (AMP) (95.1%), trimethoprim/sulfamethoxazole (SXT) (73.2%), azithromycin (ATH) (21.9%), and ciprofloxacin (CIP) (14.6%) was observed among Shigella isolates. Multidrug resistance phenotype was observed in 24.4% (10/41) of Shigella isolates, with the most common pattern of resistance to cefotaxime, ceftriaxone, ceftazidime, AMP, SXT, and ATH. This study indicates an alarming increase in the ESBL production of DEC and Shigella spp. and identifies them as the two most prevalent diarrhea-causing enteropathogens in the region. The results show that CIP could be an alternative to third-generation cephalosporins against these two pathogens. Therefore, it is proposed that further investigation be done in the pursuit of alternative antibiotics that are effective against the resistant cases. For instance, one study could look into the comparative clinical effectiveness of third-generation cephalosporins versus CIP, the latter not being presently the drug of choice for the treatment of acute diarrhea in children in Iran.</description><identifier>ISSN: 1076-6294</identifier><identifier>EISSN: 1931-8448</identifier><identifier>DOI: 10.1089/mdr.2017.0204</identifier><identifier>PMID: 29106325</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Ampicillin ; Antibiotics ; Antimicrobial agents ; Antimicrobial resistance ; Azithromycin ; Bacteria ; Campylobacter ; Cefotaxime ; Ceftazidime ; Ceftriaxone ; Cephalosporins ; Children ; Ciprofloxacin ; Developing countries ; Diarrhea ; Drug resistance ; E coli ; Epidemiology ; Escherichia coli ; Etiology ; Hospitals ; LDCs ; Microbiology ; Multidrug resistance ; Pathogens ; Salmonella ; Shigella ; Sulfamethoxazole ; Trimethoprim ; β Lactamase</subject><ispartof>Microbial drug resistance (Larchmont, N.Y.), 2017-12, Vol.23 (8), p.137-1044</ispartof><rights>2017, Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2017, Mary Ann Liebert, Inc.</rights><rights>Maneli Aminshahidi et al., 2017; Published by Mary Ann Liebert, Inc. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-e55a05a01efb7cd185aaa351852872fb259b6093ef818c17d3da7fd8064f4aae3</citedby><cites>FETCH-LOGICAL-c420t-e55a05a01efb7cd185aaa351852872fb259b6093ef818c17d3da7fd8064f4aae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29106325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aminshahidi, Maneli</creatorcontrib><creatorcontrib>Arastehfar, Amir</creatorcontrib><creatorcontrib>Pouladfar, Gholamreza</creatorcontrib><creatorcontrib>Arman, Esmayil</creatorcontrib><creatorcontrib>Fani, Fereshteh</creatorcontrib><title>Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran</title><title>Microbial drug resistance (Larchmont, N.Y.)</title><addtitle>Microb Drug Resist</addtitle><description>This study was conducted to find the etiology of acute diarrhea in Iranian children and determine the antimicrobial resistance patterns. The pathogenic bacteria were recovered from 110/269 (40.9%) diarrheal fecal samples with the following profiles: the most predominant pathogen was diarrheagenic Escherichia coli (DEC) (43.6%), comprising enteroaggregative E. coli (23.6%), enteropathogenic E. coli (10.9%), enteroinvasive E. coli (5.5%), and enterotoxigenic E. coli (3.6%); Shigella spp. (37.3%), Salmonella spp. (12.7%) and Campylobacter jejuni (6.4%) were ranked second and fourth in terms of prevalence, respectively. The rates of extended-spectrum beta-lactamase (ESBL) production were 66.7% and 53.7% in DEC and Shigella , respectively. Resistance to ampicillin (AMP) (95.1%), trimethoprim/sulfamethoxazole (SXT) (73.2%), azithromycin (ATH) (21.9%), and ciprofloxacin (CIP) (14.6%) was observed among Shigella isolates. Multidrug resistance phenotype was observed in 24.4% (10/41) of Shigella isolates, with the most common pattern of resistance to cefotaxime, ceftriaxone, ceftazidime, AMP, SXT, and ATH. This study indicates an alarming increase in the ESBL production of DEC and Shigella spp. and identifies them as the two most prevalent diarrhea-causing enteropathogens in the region. The results show that CIP could be an alternative to third-generation cephalosporins against these two pathogens. Therefore, it is proposed that further investigation be done in the pursuit of alternative antibiotics that are effective against the resistant cases. For instance, one study could look into the comparative clinical effectiveness of third-generation cephalosporins versus CIP, the latter not being presently the drug of choice for the treatment of acute diarrhea in children in Iran.</description><subject>Ampicillin</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>Azithromycin</subject><subject>Bacteria</subject><subject>Campylobacter</subject><subject>Cefotaxime</subject><subject>Ceftazidime</subject><subject>Ceftriaxone</subject><subject>Cephalosporins</subject><subject>Children</subject><subject>Ciprofloxacin</subject><subject>Developing countries</subject><subject>Diarrhea</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Epidemiology</subject><subject>Escherichia coli</subject><subject>Etiology</subject><subject>Hospitals</subject><subject>LDCs</subject><subject>Microbiology</subject><subject>Multidrug resistance</subject><subject>Pathogens</subject><subject>Salmonella</subject><subject>Shigella</subject><subject>Sulfamethoxazole</subject><subject>Trimethoprim</subject><subject>β Lactamase</subject><issn>1076-6294</issn><issn>1931-8448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>1-M</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkk1v1DAQhiMEoqVw5IosceFAFjsfTswBaSkLrbQSiJazNbEnG1eJvdgOBf4UfxFH21bABcnS2ONH78zYb5Y9ZXTFaCteTdqvCsqaFS1odS87ZqJkeVtV7f20pw3PeSGqo-xRCFeU0prx8mF2VAhGeVnUx9mvdwa8HxB2aI0im6AG9EYNBohyoyFgNbkYzA7HEci1iQM5M7uBfIaIxPVk8z2i1ajziz2q6OeJvMUI-RZUhAkCkk_e6VlF4-xrcnnt0hm1m4wFG8kmpUe3MwpGsk71Y1gk12pO2rdtEWOX-h5-viTnHuzj7EEPY8AnN_Ek-_J-c3l6lm8_fjg_XW9zVRU05ljXQNNi2HeN0qytAaCsUyzapui7ohYdp6LEvmWtYo0uNTS9bimv-goAy5PszUF3P3cTapW68zDKvTcT-B_SgZF_31gzyJ37JuuGCi54EnhxI-Dd1xlDlJMJanlGi24OkgnOaFkJUSf0-T_olZu9TeMtlEir4TRR-YFS3oXgsb9rhlG5WEEmK8jFCnKxQuKf_TnBHX379wkoD8CSBmtHgx36-B_Z3xEyw68</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Aminshahidi, Maneli</creator><creator>Arastehfar, Amir</creator><creator>Pouladfar, Gholamreza</creator><creator>Arman, Esmayil</creator><creator>Fani, Fereshteh</creator><general>Mary Ann Liebert, Inc</general><scope>1-M</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171201</creationdate><title>Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran</title><author>Aminshahidi, Maneli ; Arastehfar, Amir ; Pouladfar, Gholamreza ; Arman, Esmayil ; Fani, Fereshteh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-e55a05a01efb7cd185aaa351852872fb259b6093ef818c17d3da7fd8064f4aae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Ampicillin</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>Azithromycin</topic><topic>Bacteria</topic><topic>Campylobacter</topic><topic>Cefotaxime</topic><topic>Ceftazidime</topic><topic>Ceftriaxone</topic><topic>Cephalosporins</topic><topic>Children</topic><topic>Ciprofloxacin</topic><topic>Developing countries</topic><topic>Diarrhea</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Epidemiology</topic><topic>Escherichia coli</topic><topic>Etiology</topic><topic>Hospitals</topic><topic>LDCs</topic><topic>Microbiology</topic><topic>Multidrug resistance</topic><topic>Pathogens</topic><topic>Salmonella</topic><topic>Shigella</topic><topic>Sulfamethoxazole</topic><topic>Trimethoprim</topic><topic>β Lactamase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aminshahidi, Maneli</creatorcontrib><creatorcontrib>Arastehfar, Amir</creatorcontrib><creatorcontrib>Pouladfar, Gholamreza</creatorcontrib><creatorcontrib>Arman, Esmayil</creatorcontrib><creatorcontrib>Fani, Fereshteh</creatorcontrib><collection>Mary Ann Liebert Online - Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Microbial drug resistance (Larchmont, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aminshahidi, Maneli</au><au>Arastehfar, Amir</au><au>Pouladfar, Gholamreza</au><au>Arman, Esmayil</au><au>Fani, Fereshteh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran</atitle><jtitle>Microbial drug resistance (Larchmont, N.Y.)</jtitle><addtitle>Microb Drug Resist</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>23</volume><issue>8</issue><spage>137</spage><epage>1044</epage><pages>137-1044</pages><issn>1076-6294</issn><eissn>1931-8448</eissn><abstract>This study was conducted to find the etiology of acute diarrhea in Iranian children and determine the antimicrobial resistance patterns. The pathogenic bacteria were recovered from 110/269 (40.9%) diarrheal fecal samples with the following profiles: the most predominant pathogen was diarrheagenic Escherichia coli (DEC) (43.6%), comprising enteroaggregative E. coli (23.6%), enteropathogenic E. coli (10.9%), enteroinvasive E. coli (5.5%), and enterotoxigenic E. coli (3.6%); Shigella spp. (37.3%), Salmonella spp. (12.7%) and Campylobacter jejuni (6.4%) were ranked second and fourth in terms of prevalence, respectively. The rates of extended-spectrum beta-lactamase (ESBL) production were 66.7% and 53.7% in DEC and Shigella , respectively. Resistance to ampicillin (AMP) (95.1%), trimethoprim/sulfamethoxazole (SXT) (73.2%), azithromycin (ATH) (21.9%), and ciprofloxacin (CIP) (14.6%) was observed among Shigella isolates. Multidrug resistance phenotype was observed in 24.4% (10/41) of Shigella isolates, with the most common pattern of resistance to cefotaxime, ceftriaxone, ceftazidime, AMP, SXT, and ATH. This study indicates an alarming increase in the ESBL production of DEC and Shigella spp. and identifies them as the two most prevalent diarrhea-causing enteropathogens in the region. The results show that CIP could be an alternative to third-generation cephalosporins against these two pathogens. Therefore, it is proposed that further investigation be done in the pursuit of alternative antibiotics that are effective against the resistant cases. For instance, one study could look into the comparative clinical effectiveness of third-generation cephalosporins versus CIP, the latter not being presently the drug of choice for the treatment of acute diarrhea in children in Iran.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>29106325</pmid><doi>10.1089/mdr.2017.0204</doi><tpages>908</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1076-6294
ispartof Microbial drug resistance (Larchmont, N.Y.), 2017-12, Vol.23 (8), p.137-1044
issn 1076-6294
1931-8448
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5709696
source Alma/SFX Local Collection
subjects Ampicillin
Antibiotics
Antimicrobial agents
Antimicrobial resistance
Azithromycin
Bacteria
Campylobacter
Cefotaxime
Ceftazidime
Ceftriaxone
Cephalosporins
Children
Ciprofloxacin
Developing countries
Diarrhea
Drug resistance
E coli
Epidemiology
Escherichia coli
Etiology
Hospitals
LDCs
Microbiology
Multidrug resistance
Pathogens
Salmonella
Shigella
Sulfamethoxazole
Trimethoprim
β Lactamase
title Diarrheagenic Escherichia coli and Shigella with High Rate of Extended-Spectrum Beta-Lactamase Production: Two Predominant Etiological Agents of Acute Diarrhea in Shiraz, Iran
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A54%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diarrheagenic%20Escherichia%20coli%20and%20Shigella%20with%20High%20Rate%20of%20Extended-Spectrum%20Beta-Lactamase%20Production:%20Two%20Predominant%20Etiological%20Agents%20of%20Acute%20Diarrhea%20in%20Shiraz,%20Iran&rft.jtitle=Microbial%20drug%20resistance%20(Larchmont,%20N.Y.)&rft.au=Aminshahidi,%20Maneli&rft.date=2017-12-01&rft.volume=23&rft.issue=8&rft.spage=137&rft.epage=1044&rft.pages=137-1044&rft.issn=1076-6294&rft.eissn=1931-8448&rft_id=info:doi/10.1089/mdr.2017.0204&rft_dat=%3Cproquest_pubme%3E1961034995%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1969969760&rft_id=info:pmid/29106325&rfr_iscdi=true